Tuesday, 30 January 2018

TNF Inhibitors Market Trends with Forecast Up to 2025

TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflammation-causing substance. TNF inhibitor drugs are employed to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. Generally, in the healthy person, the TNF levels remain steady. However, in a patient with rheumatoid arthritis, the level of TNF is increasing which leads to more inflammation. TNF inhibitor drugs act as blockers for TNF substances. TNF alpha blockers are highly effective in the treatment of patients with active rheumatoid arthritis. These drugs are used in patients as a conventional second-line treatments.


Based on drug, the TNF inhibitors market can be segmented into etanercept, infliximab, adalimumab, certolizumab, and golimumab. The adalimumab segment is likely to expand at a significant pace during the forecast period. The drug is effectively used in a broad range of pain management therapies and is widely available over the counter. Based on distribution channel, the TNF inhibitors market can be segmented into hospital pharmacy and retail pharmacy. The hospital pharmacy segment is likely to expand at a significant pace between 2017 and 2025, this is because patients with rheumatoid arthritis, arthritis give more preference to the hospitals for treatment.

Increase in elderly population and rise in the prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are some of the factors that drive the TNF inhibitors market. According to the National Health Interview Survey, in 2016, almost 20% of the global population was reported to be suffering from chronic pain, with rheumatoid arthritis being one of the major reasons. Moreover, according to the Center for Disease Control and Prevention, by 2040, approximately 78 million (26%) of the U.S. adults are projected to have arthritis. Owing to this, the consumption of TNF inhibitor dugs is likely to increase rapidly in the near future. However, side-effects associated with the use of TNF inhibitor drugs such as skin irritation, flushing, headache, and abdominal pain are estimated to hinder the market in the next few years.


In terms of region, the global TNF inhibitors market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market share, primarily due to favorable reimbursement policies for pain management prescription drugs in the region. Lenient regulations in Europe are playing a key role in the increased rate of development, approval, and commercialization of innovative molecule combinations in the pain management. This is likely to fuel the market in Europe during the forecast period.

The increasing prevalent population and launching of new products are estimated to drive the market in Asia Pacific during the forecast period. Despite sustained growth and development Middle East & Africa had faced several health challenges over the last decade. Factors such as economic resources, adequate health care facilities, and growing burden of communicable diseases are likely to propel the market in the region from 2017 to 2025. Moreover, rheumatology services are limited or non-existent in several parts of sub-Saharan Africa. Hence, making these services available may boost the market in Middle East & Africa during the forecast period.

Major players operating in the global TNF inhibitors market are Pfizer, Boehringer Ingelheim, Novartis, Amgen, Mochida Pharmaceutical, Hanall, BioPharma, GalxoSmithKline, and Janssen Biotech.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Gynecology Hand Instruments Market Key Trends and Opportunity Analysis 2025

Gynecology hand instruments consist of vaginal speculum (disposable and reusable) and others including tenaculum, curettes, trocars, and biopsy forceps. Vaginal speculum is a device used to open the vaginal walls. It is generally made of metal or plastic and aids in the visual inspection of vagina and cervix. Reusable speculum was used on a large scale in the past. Currently, disposable speculum is widely used by physicians for various purposes. Major advantages of disposable over reusable speculum are high efficiency, low cost, patient care, and low risk of infection. A tenaculum is usually classified as forceps as it consists of a slim sharp-pointed hook attached to a handle. Curette is an instrument used to scrap biological tissues at the time of biopsy. Trocar is inserted into cannula that is passed into the abdominal cavity while performing laparoscopy. Trocars enable access to the intra-peritoneal cavity. Biopsy forceps are used for sharp cutting performance to regain clean specimens.


Increased rate of gynecological disorders, high preference for minimally invasive procedures for treating these disorders, rise in awareness about wellbeing, and change in the lifestyle of the female population globally are the factors fueling the growth of the gynecology hand instruments market in terms of revenue. However, required amount of documentation and high cost for the U.S. FDA approval could delay the process of device approval. Moreover, the U.S. FDA is considering a ban on morcellation in minimally invasive hysterectomies due to high incidence of undiagnosed sarcoma reported in women undergoing these procedures. This hinders the growth of the market.
The global gynecology hand instruments market can be segmented based on product type and region. In terms of product type, the market can be divided into vaginal speculum and others. Vaginal speculum can be classified into disposable and reusable. The others segment can be sub-segmented into biopsy forceps, tenaculum, trocars, and curettes.

Geographically, the global gynecology hand instruments market can be segmented into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. North America accounted for the largest market share in 2016. Dominance of this region is attributed to increased preference for minimally invasive procedures, availability of technologically advanced devices, and growing awareness about wellbeing. North America is expected to continue its dominance in the market during the forecast period. Technologically advanced devices and high reimbursement are likely to support market growth in the region.


Asia Pacific held the second largest market share in 2016. The gynecology hand instruments market in Asia Pacific is expected to expand at the highest CAGR in 2025. This is attributed to increase in demand for gynecological hand instruments due to introduction of technologically advanced minimally invasive hand instruments that assist in performing certain gynecological procedures in office settings at low cost. Existence of a large patient pool, increase in government funding and developmental initiatives in health care facilities, changes in lifestyle of the population, and improvement in medical insurance policies are the major drivers of the market in Asia Pacific. Europe is anticipated to grow during the forecast period driven by rise in awareness about the efficacy of innovative gynecological hand instrument devices among gynecologists.

The gynecology hand instruments market in Latin America is anticipated to grow during the forecast period owing to rising trend of minimally invasive surgeries especially for gynecological procedures. Developing economic conditions and increasing awareness about new technology, diagnosis, and treatment alternatives have supported the growth of the gynecology hand instruments market in Latin America. The market in Middle East & Africa is anticipated to grow during the forecast period from 2017 to 2025 due to rise in prevalence of gynecological disorders, increase in awareness about available gynecological treatments, and initiatives taken by the government and international organizations in these countries. Moreover, increase in funding provided by governments and international health associations, rise in educated population, and privatization of health care infrastructure are anticipated to contribute to market growth.


Key players operating in the global gynecology hand instruments market include Medtronic, CooperSurgical, Inc., Ethicon US, LLC, Hologic, Inc., KARL STORZ Se & Co. KG, and Olympus Corporation.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Vacuum-assisted Fetal Delivery Systems Market Industry Insights, Outlook and Forecast Up to 2025

Numerous techniques are utilized by health care professionals to assist pregnant women during labor. Vacuum-assisted delivery of fetus is one of the popular techniques of vaginal delivery being adopted by gynecologists as well as patients across the globe. The vacuum-assisted delivery is preferred in cases of rupturing of uterine membranes, prolonged second stage of labor, and other complications associated with the final term of pregnancy. If the vacuum cup is properly placed and the vacuum (traction) is exerted in line with the pelvic axis, incorrect position of the head of the fetus can be corrected. In order to reduce the risk of neonatal morbidity, proper placement of cups over the specific flexion point is essential to maintain the vacuum integrity.


Attempts being made to reduce the uterine extension during delivery and the complications associated with it in critical cases is a major factor expected to drive the market for vacuum-assisted fetal delivery systems during the forecast period. However, post-delivery maternal complications such as anal sphincter injury, hemorrhage, uterine atony, and anemia and reducing preference for vaginal birth by mothers are factors likely to restrain the market for vacuum-assisted fetal delivery systems between 2017 and 2025.

The global vacuum-assisted fetal delivery systems market has been segmented based on product and end-user. In terms of product, the market has been further segmented based on cup shape, cup material, and cup type. Based on cup shape, the market has been divided into mushroom–shaped cups, bell–shaped cups, and others. The bell-shaped cups segment dominated the market in 2016, in terms of revenue. The segment is expected to continue its dominance throughout the forecast period, which is attributable to the flexible stem of bell-shaped cups enabling the placement of the cup over the flexion point, irrespective of the position of the fetal head. Based on cup material, the market has been classified into silicon and stainless steel. The silicon segment is estimated to expand at the maximum CAGR during the forecast period, owing to strong support offered by silicon cups in case of caesarean delivery and their ability to attach to the fetal scalp gently. Based on cup type, the market has been segregated into disposable cups and reusable cups. The disposable cups segment accounted for the highest revenue in 2016, owing to reduced rates of cross contamination during the fetal delivery procedure, and growing preference of healthcare providers for disposable cups.


Based on end-user, the global vacuum-assisted fetal delivery systems market has been segmented into hospitals, specialty clinics, ambulatory surgical centers, and others. The hospitals segment accounted for a leading market share in terms of revenue in 2016, which is attributable to the rapidly increasing number of birth rate across the globe and availability of trained and well-qualified health care professionals in hospitals worldwide.

Geographically, the global vacuum-assisted fetal delivery systems market has been segmented into five major regions viz. North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the maximum market share in 2016, due to strategic presence of key players in the U.S. and Canada and rising demand from mothers for safe delivery without post-delivery complications. Europe is considered the second most prominent market for vacuum-assisted fetal delivery systems. On the other hand, the market in Asia Pacific is likely to register the maximum CAGR from 2017 to 2025, which is attributable to the introduction of suction cups with a novel design that allows safe attachment of the cup to the fetal scalp and easy handling offered by suction cups during critical positioning of the fetal head.

Prominent players operating in the global Vacuum-assisted Fetal Delivery Systems Market are CooperSurgical, Inc., Clinical Innovations, LLC, Medela Healthcare, Utah Medical Products, Inc., Benetec Medical Systems, and Medisil Engineers.


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Generalized Anxiety Disorder Market Growth Opportunities and Forecast Up to 2023

Generalized anxiety disorder is characterized by excessive anxiety and worry about everyday life events with no apparent reason. The patient cannot stop worrying about health, family, money, or work and eventually anxiety dominates the person thinking, that interfere with daily functioning of person. Symptoms of generalized anxiety disorder includes an unrealistic view of problems, muscle tension, headache, sweating, and tiredness. Additionally, rarely GAD occurs alone as it often accompanied by other anxiety disorder, substance abuse, and depression. Number of factors are responsible to develop GAD which includes genetics, brain chemistry, and environmental factors such as trauma and stressful event, family background, or life experiences.


The disorder comes on progressively and can arise across the life cycle, though the risk is highest between childhood and middle age. GAD is diagnosed when a person worries excessively of everyday problems for more than six months and has three or more symptoms. According to Centers for Disease Control and Prevention (CDC), prevalence of anxiety disorder in Europe is over 15 % of total Europe population. In addition, CDC stated that prevalence of disorder is more in women than men. Generally, psychotherapy is preferable to GAD patient before medication which teaches a person different ways of reacting, and thinking in various life situations.

Generalized anxiety disorder market is segmented into therapeutics, and geography. The therapeutics market is segmented into antidepressant, buspirone, and benzodiazepines. Antidepressants further segmented into selective serotonin reuptake inhibitor (SSRI), and serotonin norepinephrine reuptake inhibitor(SNRI). Benzodiazepines includes alprazolam (Niravam, Xanax), chlordiazepoxide (Librium), diazepam (Valium) and lorazepam. However, benzodiazepines can be habit forming hence, generally used for short term basis and consider as a last choice of treatment. Antidepressant are first line therapy for GAD patient hence, hold the largest market share globally.


Geographically, generalized anxiety disorder market segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and Rest of the World (RoW). North America dominates the global generalized anxiety market due to increasing incidence of anxiety disorders, and more awareness in people related to anxiety and it is expected to maintain the position during forecast period. However, Asia Pacific market is expected to grow at a faster rate due to changing lifestyle lead to increasing stress, and growing facilities to detect anxiety disorders.

Some of the major driving factors to propel the generalized anxiety disorders market are increasing incidence rate due to more stressful life, Sedentary lifestyle, and presence of strong pipeline. According to National Institute of Mental Health, every year GAD affects minimum 6.8 million adults, or 3.1% of the U.S. population. In the National Comorbidity Survey carried out in 2005, 58% of patients diagnosed with major depression were found to have an anxiety disorder; among these patients, the rate of comorbidity with GAD was 17.2%. However, poor diagnosis rate as no single diagnosis test is available to detect generalized anxiety disorder, affectivity of psychotherapy, and side effects of medications such as habit forming nature, dry mouth, and nausea could restraint the market growth. Focusing on emerging countries such as BRICS countries would create an opportunity for a market players.


Some of the key players of the global generalized anxiety disorder market are Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer, Inc., Abbott Laboratories, Baxter International, Bristol-Myers Squibb, Actavis Pharmaceutical Company, F. Hoffmann-La Roche, Recordati Rare Diseases, Noven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma, and Shionogi and Company.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Postmenopausal Vaginal Atrophy PVA Drugs Market Key Growth Factors and Forecast Up to 2023

Postmenopausal Vaginal Atrophy (PVA) refers to decrease in estrogen production most commonly after menopause and the condition is also called as vaginal Atrophy. Less estrogen leads to drying, thinning, and decreased elasticity of vaginal tissues. Various other causes leading to decrease in estrogen levels include perimenopause, during breast feeding, surgical menopause, pelvic radiation therapy and chemotherapy and also as a side effect of breast cancer hormonal treatment. Symptoms of vaginal Atrophy include burning, redness, itching, dyspareuia, and irritation. Vaginal atrophy is a common result of the treatment of many gynecological cancers. Postmenopausal vaginal Atrophy is known to occur commonly due to increase in life expectancy and lengthening of average lifespan post menopause. Diagnosis for PVA includes pelvic examination, vaginal smear test, vaginal activity test, blood test and urine test.


The treatment generally involves use of hormonal replacement therapy, estrogen creams, pessaries or lubricating gels. The sensitivity of urogenital tract to the decline in estrogen levels leads to symptoms related to vaginal atrophy, and is also known to affect sexual function and quality of life in about half of all postmenopausal women. Most commonly, vaginal atrophy becomes evident 4–5 years post the menopause. The principles of treatment in women with established vaginal atrophy are restoration of urogenital physiology, and alleviation of symptoms.

The global PVA drugs market can be segmented based on therapy type, pipeline analysis and geography. Therapy type includes estrogen based and non estrogen based. Commonly used estrogen based therapy includes topical estrogen and systemic estrogen. Various formulations used in topical therapy include creams, tablets and rings, while systemic therapy includes oral administration of estradiol. Vaginal creams and vaginal tablets are the most commonly used therapies. However, topical estrogen treatment is known to cause endometrial cancer in few women Oral estradiol use since associated with adverse events such as deep vein thrombosis, stroke, Coronary Heart Disease (CHD), and invasive breast cancer is least preferred treatment option.


Recent novel drugs in non estrogen category include Osphena (osphemifene), BZA/CE (bazedoxifene + conjugated estrogens) and Vaginorm (prasterone). Estrogen replacement therapy producst include Premarin, Vagifem, Estrace, Estring and Femring. Geographically, the global PVA drugs market can be segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World.

Historically, PVA has witnessed several unmet needs due to low diagnosis rate, poor patient compliance and the risk associated with the existing treatment to cause different cancers. Also, the reluctant nature of women to discuss with healthcare professionals regarding symptoms such as vaginal burning vaginal dryness, and discomfort during intercourse was known to result in low diagnosis and treatment-seeking rate. However with the advent of novel drugs with improved safety are expected to tap the unmet needs by increasing the number of women undergoing treatment. Increase in awareness of postmenopausal vaginal Atrophy amongst patient as well as physicians regarding the need for treatment, shift towards use of non-estrogen based therapies and conducting awareness campaigns is likely to boost the PVA drugs market during the forecast period. Novel drug are further expected to improve patient compliance through enhanced safety and efficacy profiles and therefore drive the global postmenopausal Atrophy drugs market.


Some of the key players contributing to the global postmenopausal vaginal Atrophy drugs market include Actavis plc, Bionovo, Inc., Endoceutics, Inc., Novo Nordisk A/S, Pfizer, Inc., Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., and Shionogi & Co. Ltd.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Pyrimethamine Treatment Market Trends with Forecast Up to 2023

Pyrimethamine is a medication used for protozoan infections. It is commonly used as an antimalarial drug (for both treatment and prevention of malaria), and to treat Toxoplasma gondii infections, particularly when combined with the sulfonamide antibiotic sulfadiazine when treating HIV-positive individuals. Pyrimethamine is typically given with a sulfonamide and folinic acid due to its resistance against many Plasmodium species. Pyrimethamine has also been found to limit the expression of the superoxide dismutase 1 gene, a protein involved in amyotrophic lateral sclerosis.
Pyrimethamine is considered in the list of one of the most important medications by World Health Organization’s list of essential medicines. Pyrimethamine’s ability to cure protozoan infection and toxoplasma infections, rising number of HIV positive patients worldwide and immunosuppressed individual at a risk of infections are the factors driving the pyrimethamine treatment market during the forecast period. Moreover, mergers and acquisitions by the manufacturing companies would also the boost the demand and supply for the pyrimethamine medication in the pyrimethamine treatment market.
However, the certain side effects that may occur with pyrimethamine medication include allergic reactions, blood disorders, tongue changes, blood in the urine, heart rhythm disorders, anorexia, and vomiting (see Important Safety Information below) which act as a restraining factor for the growth of this market. Additionally, factors such as pricing issues in some countries and resistance developing against the drugs may hamper the growth of the pyrimethamine treatment market during the focus period of 2013 to 2023.
The global pyrimethamine market has been segmented into brands and geography. On the basis of brand, the pyrimethamine treatment market has been segmented into two drugs that are presently marketed such as Daraprim and Fansidar. The Daraprim sub-segment held the largest share for the pyrimethamine treatment market. However, the Fansidar sub-segment is growing at a high rate due to affordable cost and availability.
Geographically, North America dominates the global pyrimethamine treatment market followed by Europe. The market domination was majorly due to the pricing structure of the pyrimethamine drug in the U.S. The High prevalence of toxoplasma in the region also acts as the driving factor for the growth of the pyrimethamine treatment in the North America. According to The Centers for Disease Control and Prevention (CDC), toxoplasmosis is one of the five neglected parasitic infections in the U.S.
It is the second leading cause of death from foodborne illness in the country and more than 60 million people in the U.S. carry the toxoplasma parasite, and more than one million people in the U.S. are infected annually with the toxoplasma parasite, which is associated with high rates of morbidity and mortality. Asia-Pacific is also increasing constantly in the pyrimethamine drugs market mainly due to the high prevalence of protozoan disease such as malaria in India, China and other developing nations. Moreover, government initiatives and regulatory norms in these countries would fuel the market for pyrimethamine treatment market in the region during the forecast period. Latin America is also a growing market for pyrimethamine treatment due to developing healthcare expenditure and high prevalence rate of malaria and toxoplasma in the region.
Some of the major players in pyrimethamine treatment market include Turing Pharmaceuticals, Impax Laboratories, Inc., Pfizer, Inc. GlaxoSmithKline plc, and others.
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:

Gerontology/Aging Market Key Trends and Opportunity Analysis 2024

Gerontology is an integrative study of aging which comprises the biological, psychological, sociological, and economical aspects of aging. It involves the study of aging from the individual as well as from the societal perspective. Gerontology study works in a variety of settings such as health facilities, mental health services, social service agencies, marketing and communications, retirement planning, recreation and leisure, housing agencies, government agencies, community agencies, advocacy groups, or research and educational institutions.


Global gerontology/aging market is anticipated to witness a boost over the forecast period due to factors such as increasing geriatric population all over the world and rising disorders and diseases related to aging. The rate of gerontology care services and institution is increasing globally aiming to train professionals to deal with various aspects of geriatric population. These professionals work in different industries including health care, government, business community and non-profit organizations. Additionally, the continuous up gradation of in therapeutic favoring the increased life span and health care services are improving the life expectancy of aged people. These factors collectively will drive the gerontology/aging market in the forecast period.

Gerontology/aging market can be segmented on the basis of its application into social, environmental and biogerontology. The scope of these applications can be functional in health care, business communities, non-profit organizations, hospitality, wellness and fitness centers for the geriatric people. Social gerontology deals with carrying out social research surveys dealing with the civic attitude towards the elderly and developing solutions and technologies that would make life safer and easier for this population. This segment also focuses in maintaining healthy environment between geriatric population and their families and providing home health care services and practicing geriatric social work.


Environmental gerontology segment attempts to understand the multifaceted relationship with the environment, including home and family, neighborhood and region to enable social and environmental programs that enable successful aging. Biogerontology focuses on research in biological aging processes, its causes, effects and mechanism. The growing numbers of institution and care centers globally, are anticipated to boost the global gerontology/aging market during the forecast period.

Geographically, North America accounts for one of the largest markets followed by Europe. Baby boomers play a major role in the market growth. According to the U.S. Census Bureau, the average life expectancy in the U.S. will be 77.1 years for men and 81.9 years for women by 2020. To tackle the rising aging population, favorable reimbursement policies and extensive presence of care centers are set up to assist the problems faced by aged people. Asia Pacific is anticipated to be the fastest growing region due to the factors such as rise in persistent medical conditions and rising concern for life expectancies among the geriatric population. Latin America holds a strong potential for the market growth owing to the high presence of geriatric population and growing health care facility.


Some of the key players in this market segment are, the Jewish Family Service, the International Association of Geriatric Care, National Association of Professional Care Managers, Senior Care Centers, the UF health, the World Health Organization and others. These players constantly participate in awareness programs, as well as mergers and acquisitions to serve the elderly society effectively.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)